What is LXEO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.27B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LXEO?

P/E (TTM) is n/a and 52-week range is $2.98 to $10.99 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LXEO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LXEO?

The company profile lists revenue (TTM) near $495K, net income (TTM) near $-5.94B, EPS (TTM) near $-1.16 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Lexeo Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in New York City, New York, US, 78.5M shares outstanding, ISIN US52886X1072 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Lexeo Therapeutics Inc

$LXEO

Health Care · Biotechnology

Run Scenarios

$3.23

+0.62%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Lexeo Therapeutics, Inc. is a clinical stage genetic medicine company, which engages in the development of therapies for hereditary and acquired diseases. The company is headquartered in New York City, New York and currently employs 59 full-time employees. The company went IPO on 2023-11-03. Using a stepwise development approach, the Company is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimers disease programs. Its pipeline consists of candidates targeting patient populations. Its most advanced cardiovascular product candidate, LX2006 for the treatment of patients with Friedreichs ataxia (FA), cardiomyopathy, is being evaluated in SUNRISE-FA, an ongoing Phase I/II clinical trial. Its second most advanced cardiovascular product candidate, LX2020 for the treatment of arrhythmogenic cardiomyopathy, caused by mutations in the PKP2 gene (PKP2-ACM), received IND clearance from the United States Food and Drug Administration (FDA).

Employees

Website

www.lexeotx.com/

IPO

2023-11-03

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)